Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by educational grants from Servier Pharmaceuticals LLC.

Patient & Provider Connection™: Understanding the Patient Journey During the Management of Acute Lymphoblastic Leukemia

Release Date: March 16, 2021
Expiration Date: March 16, 2022

Activity Overview

In recent years, significant progress has been made in understanding the pathophysiology of acute lymphoblastic leukemia (ALL), including identification of new cytogenetic and molecular abnormalities and development of novel targeted agents. The addition of tyrosine kinase inhibitors (TKIs), monoclonal antibodies, novel immune therapies including bispecific T-cell engager and chimeric antigen receptor (CAR) T cells to the treatment landscape has resulted in improved clinical outcomes. These new developments have shifted clinical management to a more individualized treatment approach based on immunophenotypic, cytogenetic and molecular features.

This video-based activity is designed for health care professionals to explore the diagnosis and treatment of ALL through a unique perspective that puts the patient voice front and center. In addition to renowned expert, Daniel J. DeAngelo, MD, PhD, who will discuss implementation of current and emerging treatment options in the management of ALL, a pediatric ALL survivor will lend her expertise by sharing her personal journey of living with ALL. The activity focuses on steps along the continuum of care: screening, diagnosis, and referral to initiation of treatment, treatment during disease progression, management of adverse events, and shared decision-making that occurs along the way.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Servier Pharmaceuticals LLC.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward medical oncologists, hematologists, and nurses who treat patients with acute lymphoblastic leukemia (ALL).

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Detail risk stratification strategies in ALL to help develop appropriate treatment plans in pediatric and adult patients.
  • Evaluate current and emerging clinical data regarding treatment options for ALL, including the role of MRD in prognosis and treatment decision-making for patients with ALL.
  • Outline strategies to maintain and improve patients’ quality of life during the diagnostic and treatment journey in ALL, including adverse event mitigation and management.
  • Apply current and emerging treatment strategies to clinical scenarios to improve outcomes for patients with ALL.

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.


Daniel J. DeAngelo, MD, PhD
Daniel J. DeAngelo, MD, PhD
Chief of the Division of Leukemia
Department of Medical Oncology
Dana-Farber Cancer Institute
Boston, MA
Professor of Medicine
Harvard Medical School
Boston, MA

Disclosures: Grant/Research Support: AbbVie, Novartis, Blueprint, GlycoMimetics. Consultant: AbbVie, Amgen, Agios, Blueprint, FortySeven, GlycoMimetics, Incyte, Jazz Pharmaceuticals, Kite, Novartis, Pfizer, Servier, Takeda.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By